2 September 2010: Australian public companies are increasingly attracting international investment from US and European companies through creative methods of financing, says Australia’s biotechnology industry organisation, AusBiotech. The global financial crisis has seen more Australian biotechnology companies looking toward alternative methods of financing to capitalise on global opportunities.
In the current economic climate, investors are looking for higher, alternative sources of income. Creative funding, including hybrid investments, royalty investments and debt equity investments, provide companies with flexible and less expensive sources of capital to fund their commercialisation or development efforts.
Creative global investors will outline new developments and innovative financing options from an international perspective at AusBiotech 2010 in an investment session titled ‘International financing – new options and opportunities’.
The session, to be held on the Wednesday morning of AusBiotech 2010 in Melbourne from 19 – 22 October, will outline several new finance options available and introduce key international investors who have invested and are interested in investing in Australian life sciences companies.
“Interest in traditional forms of capital is waning during these tough economic times,” said AusBiotech Chief Operating Officer, Glenn Cross. “Smart Australian biotechnology companies are revaluating their finance options and increasingly taking a more creative approach, with excellent results.”
Key and international speakers at the session include:
• Jeremy Curnock-Cook, Managing Director of IB Australia Bioscience Fund
• Dr Selena Chaisson, Director of Healthcare Developments at Bailard, US
• Malcolm Thompson, La Jolle Cove Investors, US
• Philip Valliere, Senior Vice President at SpringTree Global Investors, US
• Todd C David, Cowan Healthcare Royalty Partners, US
AusBiotech 2010 is the annual conference of AusBiotech and the premier biotechnology conference for Australia and the Asia-Pacific. The conference attracts over 1400 delegates from across the world each year and is renowned for its agenda-setting programs, significant business analysis and world-class Business Matching Program.
For additional event information visit the conference website at: www.ausbiotech2010.com.au.
About AusBiotech
AusBiotech is Australia’s voice on biotechnology, and represents more than 3,000 members, encompassing medicines, medical diagnostics and devices, agriculture, alternative fuels and climate change.
